Differential Effects of Vasopressin and Oxytocin on Attention Control

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Drug: Placebo; Drug: Vasopressin; Drug: Oxytocin

• Registration Number: NCT04715737
• Lead Sponsor: University of Electronic Science and Technology of China

Brief Summary

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) and oxytocin (24IU) have differential effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Detailed Description

Previous studies have demonstrated intranasal vasopressin and oxytocin's divergent effects on social behavior and emotion processing such as empathy and negative emotion processing, however, it remains unclear whether vasopressin and oxytocin treatment would have differential effects on attention processing to social stimuli. Based on the previous registered studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) from our group using a validated emotional anti-saccade task with social stimuli (emotional faces) and non-social stimuli (oval shape) have separately explored intranasal vasopressin and oxytocin's modulatory effects on attention processing, the present study aims to conduct a secondary analysis of the previously acquired data to directly compare vasopressin and oxytocin's effects on attention control to social emotional stimuli. To this end data from subjects who underwent intranasal oxytocin administration (n = 33; NCT03486925) will be compared with data from subjects who underwent intranasal vasopressin or placebo administration (n = 39, or 45 respectively; NCT04493554). To further control for non-treatment related factors the intranasal placebo groups from the previous studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) will be compared with respect to primary and secondary outcome measures of the trial, in particular general and emotion-specific effects on attentional control.

Study Timeline

• Study Start: 2017-12-19
• Status Verified: 2021-01
• Primary Completion: 2021-01-01
• Study Completion: 2021-01-01
• Study First Submitted: 2021-01-14
• Study First Submitted QC: 2021-01-14
• Study First Posted: 2021-01-20
• Last Update Submitted: 2021-01-20
• Last Update Posted: 2021-01-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 160

Inclusion Criteria

• Male, healthy participants
• Non smokers

Exclusion Criteria

• Previous or current medical, psychiatric, neurological disorder
• Regular medication
• Use of any psychoactive substances in the 24 hours before experiment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo intranasally
Vasopressin	Vasopressin	Vasopressin (20IU) intranasally
Oxytocin	Oxytocin	Oxytocin (24IU) intranasally

Primary Outcome Measures

Name	Time	Method
Differential effects of intranasal vasopressin and oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli	Time Frame: 45 minutes - 100 minutes after treatment	Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions
Differential effects of intranasal vasopressin and oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli	Time Frame: 45 minutes - 100 minutes after treatment	Comparison between social-specific error rates of saccade/antisaccade between the vasopressin, oxytocin and placebo treatment conditions

Secondary Outcome Measures

Name	Time	Method
Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade latencies towards the separate facial emotions	Time Frame: 45 minutes - 100 minutes after treatment	Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions
Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade error rates for the separate facial emotions	Time Frame: 45 minutes - 100 minutes after treatment	Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin, oxytocin and placebo treatment conditions

Trial Locations

Locations (1)

University of Electronic Science and Technology of China (UESTC); 🇨🇳 Sichuan, Chengdu, China